4/A: Akari Therapeutics Director Amends Filing to Correctly Report ADS Transaction
SEC Form 4/A Amendment
An Akari Therapeutics director, Abizer Gaslightwala, amended a previous SEC filing to correct the number of American Depository Shares (ADS) purchased and the total amount beneficially owned.
Summary
- Abizer Gaslightwala, a director of Akari Therapeutics Plc, filed an amendment to a Form 4, originally filed on January 13, 2025.
- The amendment corrects the number of American Depository Shares (ADS) acquired on January 10, 2025, and the total amount of securities beneficially owned following the transaction.
- The director initially reported purchasing 11,439 ADS at $1.22 per ADS, but the correct amount was 11,640 ADS at prices ranging from $1.22 to $1.28 per ADS.
- The total amount of securities beneficially owned following the transaction was initially reported as 35,860, but the revised amount is 47,500 ADS.
Sentiment
Score: 5
Explanation: The document is a routine correction of a previous filing, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- The correction of the filing ensures accurate information is available to shareholders and potential investors.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of the initial transaction involving the acquisition of American Depository Shares (ADS). |
| 01/13/2025 | Date of the original Form 4 filing which contained incorrect information. |
| 02/07/2025 | Date of the amended Form 4/A filing to correct the previously reported information. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.